Number of in vitro susceptible isolates (%)*
| Species | Number of isolates† | Meropenem | Piperacillin-tazobactam | Gentamicin | Ciprofloxacin | Beta-lactamase | |
| ESBL n=247 | Escherichia coli | 203 | 203 (100) | 175 (86) | 153 (75) | 97 (48) | na |
| Klebsiella pneumoniae | 35 | 34 (97) | 17 (49) | 26 (74) | 6 (17) | na‡ | |
| Klebsiella oxytoca | 6 | 6 (100) | 4 (67) | 2 (33) | 1 (17) | na | |
| Other§ | 2 | 2 (100) | 1 | 1 | 1 | na | |
| CPE n=6 | E. coli | 3 | 0 | 0 | 1 (33) | 0 | OXA-48 (2), NDM (2)¶ |
| Other** | 3 | 0 | 0 | 2 (67) | 0 | NDM (3) |
*According to European Committee on Antimicrobial Susceptibility testing (EUCAST) breakpoints (www.eucast.org).
†Eleven patients were colonised with more than one ESBL-producing enterobacteria and two patients were colonised with two different CPE (different species or susceptibility pattern).
§One Klebsiella spp, and one Citrobacter koseri.
‡One isolate of K. pneumoniae was both ESBL and New Delhi metallo-beta-lactamase (NDM) positive.
¶One isolate was both oxacilinase-48 (OXA-48) and NDM positive.
**One Enterobacter cloacae, one K. pneumoniae and one Citrobacter freundii.
CPE, carbapenemase-producing enterobacteria; ESBL, extended-spectrum beta-lactamase-producing enterobacteria; na, not available.